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We showed previously that GnRH receptors are expressed in melanoma cells; their activation
reduces cell growth andmetastatic behavior. Here, we investigatedwhether GnRH agonistsmight
affect the expression of genes involved inmelanomaprogression. By genome-wide transcriptomic
and real-time PCR analysis, we first observed that GnRH agonists decrease the expression of the
pro-angiogenic factor vascular endothelial growth factor (VEGF) (all isoforms) in BLM melanoma
cells. Then, we demonstrated that GnRH agonists specifically decrease the expression of the
VEGF165 isoform as well as its secretion from BLM cells. These data suggested that activation of
GnRH receptors might reduce the pro-angiogenic behavior of melanoma cells. To verify this hy-
pothesis, we treated BLM cells with a GnRH agonist; the conditionedmedium from these cells was
tested to assess its capability to stimulate human umbilical vein endothelial cell (HUVEC) motility.
ThemigrationofHUVECs towards the conditionedmediumofGnRHagonist-treatedBLMcellswas
significantly lower than the migration of HUVECs toward the conditioned medium of untreated
cells. Thus, GnRH agonists reduce the pro-angiogenic behavior of melanoma cells through a de-
creased production of bioactive VEGF. We then found that GnRH receptors are also expressed on
HUVECs and that GnRH agonists reduce their ability to proliferate and to form capillary-like tubes
when stimulated by VEGF. These findings suggest that GnRH agonists exert an anti-angiogenic
activity indirectly by decreasing VEGF secretion from tumor cells and directly by counteracting the
pro-angiogenic activity of the growth factor. These data might lead to the development of novel
targeted approaches for melanoma. (Endocrinology 151: 4643–4653, 2010)
The incidence of cutaneous melanoma keeps increasing(1); thus, despite the improving in early diagnosis allow-
ing curative surgical strategies, this pathology remains the
leadingcauseof skincancerdeaths indevelopedcountries (2,
3). In its late stages, cutaneousmelanoma is characterized by
a high proliferation rate and by a strong ability to give rise to
metastases (4, 5). In this context, the process of angiogenesis
plays a crucial role by inducing formation of a new vascu-
lature (6).Newblood vessels provide the adequate supply of
oxygen and nutrients to melanoma cells and allow their dis-
semination to distant organs (6). Accordingly, melanoma
cells have been shown extensively to secrete high amounts of
vascular endothelial growth factor (VEGF), the most selec-
tive stimulator of rapid angiogenesis (7, 8).
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The prognosis of highly aggressive, metastatic mela-
noma is still very poor because of the resistance of the
disseminated tumor to standard chemotherapy (9, 10).
Cytotoxic compounds, such as dacarbazine, have been
reported to be associatedwith amodest antitumor activity
and significant side effects (11). Immunotherapy has dem-
onstrated response rates of approximately 15–20% with
only a slightlymore durable response than that foundwith
chemotherapy (10, 12, 13). Based on these disappointing
observations, major efforts are now given to unraveling
themolecularmechanisms underlyingmelanomaprogres-
sion toward its most proliferative, metastatic, and pro-
angiogenic stage. Specifically, a better understanding of
the mechanisms controlling the expression/activity of the
VEGF system might stimulate the development of inno-
vative, and hopefully more successful, targeted therapeu-
tic strategies. To this purpose, it must be underlined that
clinical trials based on VEGF-targeted therapies are at
present ongoing in melanoma patients (14, 15).
GnRH is the hypothalamic decapeptide that is well
known for its central role in the control of the reproductive
axis (16). GnRH exerts its activity by binding to Gq/
phospholipase C-coupled receptors (GnRH-R) on pitu-
itary gonadotropes (16). Chronic administration of GnRH
agonists induces desensitization of GnRH-R, thus sup-
pressing the function of the pituitary-gonadal axis. Based
on this mechanism of action, GnRH analogs are widely
and successfully used for the treatment of hormone-de-
pendent pathologies, such as tumors of the reproductive
tract (prostate, breast, endometrium) (17–19). GnRH is
also well known as an autocrine/paracrine factor that is
expressed, together with its receptors, in tumors of the
reproductive system, inwhich it acts as a local regulator of
tumor growth (20–25). In particular, our laboratory has
extensively demonstrated that GnRH agonists significantly
reduce the growth and the metastatic behavior of prostate
cancer cells, both androgen dependent and androgen inde-
pendent (23–25), and that tumor GnRH-R are specifically
coupled to the Gi-cAMP intracellular signaling pathway
(26). Similarobservationshavebeenwidely reportedalso for
tumors of the female reproductive tract, such as ovarian and
endometrial cancers (27, 28). Thus, it is suggested that these
compounds might exert an additional and direct antitumor
activity on tumors expressing GnRH-R.
In previous studies, we demonstrated that Gi-coupled
GnRH-R are also expressed in melanoma cells; activation
of these receptors significantly reduces the proliferative as
well as the migratory/invasive behavior of these cells (29–
31). The possible effect of GnRH agonists on the process
of angiogenesis in melanoma has never been investigated.
Here, we demonstrate that GnRH agonists signifi-
cantly decrease the expressionofVEGF inmelanomacells,
followed by reduction of its secretion and activity. Sur-
prisingly, we found that GnRH-R are also expressed in
human umbilical vein endothelial cells (HUVECs) and
that their activation interferes with VEGF-induced cell
proliferation and ability of tube formation. Thus,we dem-
onstrate a dual targeting of both cancer and endothelial
cells by GnRH agonists and hypothesize its role in reduc-
ing the angiogenic behavior of melanoma cells.
Materials and Methods
Chemicals
The GnRH agonist Goserelin acetate [D-Ser(tBu)6Aza-Gly10-
GnRH; Zoladex] (GnRH-A) was kindly provided from Astra-
Zeneca Pharmaceuticals (Macclesfield, Cheshire, UK). The GnRH
antagonist Antide [N-Ac-D-Nal1-D-Cpa2-D-Pal3-Ser4-Lys(Nic)5-D-
Lys(Nic)6-Leu7-Ilys8-Pro9-D-Ala10-NH2 (GnRH-Ant)] was pur-
chased from Sigma (St. Louis, MO). The pro-angiogenic factor
VEGF165 was from R&D System (Minneapolis, MN).
Cell cultures
The human melanoma BLM cell line was kindly donated by
Dr. G. N. vanMuijen (Department of Pathology, Radboud Uni-
versity NijmegenMedical Center, Nijmegen, The Netherlands).
BLM cells were cultured in DMEM (Seromed Biochrom KG,
Berlin, Germany), supplemented with 10% fetal bovine serum
(FBS) (Invitrogen, Paisley, Scotland, UK), glutamine (1 mM), an-
tibiotics (100 IU/ml penicillin G sodium, and 100 g/ml strep-
tomycin sulfate) and sodium pyruvate (100 nM). Cells were
grown at 37 C in a humidified atmosphere of 5%CO2/95% air.
A panel of human melanoma cell lines (kindly provided by
Meenhard Herlyn, Wistar Institute, Philadelphia, PA) derived
from tumors at different stages of progression were available at
the Department of Oncology, Mario Negri Institute (Milan,
Italy) (32). WM793, WM902, WM1341, and WM1552 cells
were isolated from nonmetastatic primary lesions; WM115,
WM278A, and WM 983A cells derive from cutaneous primary
lesions that originatedmetastatic disease fromwhichWM239A,
WM1617, andWM983Bcellswere isolated, respectively.WM373
andWM9 cells were also frommetastases. All the cell lines were
grown in RPMI 1640 medium (Invitrogen) supplemented with
5% heat-inactivated FBS and 1% L-glutamine.
HUVECs were obtained as described previously (33) and
grown in M199 medium supplemented with 20% FBS, glu-
tamine (1 mM), antibiotics (100 IU/ml penicillin G sodium and
100g/ml streptomycin sulfate), 20mMHEPES, 6 IU/ml heparin
(Bio Spa, Milan, Italy), and endothelial cell growth supplement
(BDBiosciences, San Jose, CA). Cells weremaintained at 37C in
a humidified atmosphere of 5%CO2/95% air. All cultures were
verified to be Mycoplasma free.
RT-PCR analysis of GnRH-R mRNA
Total RNAwas prepared with the use of the RNeasy mini kit
(Qiagen, Chatsworth, CA), according to the instructions of the
manufacturer. RT was performed on 1 g of total RNA. cDNA
synthesis was performed using the Gene AMP Gold RNA PCR
Reagent kit (Applied Biosystems, Foster City, CA), with an
oligo(dT)16 as a primer for the RT. Samples containing cDNAs
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were then amplified in a 50 l solution containing PCR buffer
(150 mM Tris-HCl, 100 mM KCl, 1.75 mM MgCl2, 0.8 mM
dNTP, and 2.5 U of AmpliTaqGoldDNA). PCRwas performed
for 35 cycles (1-min denaturation at 94 C, 1-min primer anneal-
ing at 58 C, and 2-min primer extension at 72 C) in the presence
of the following primers: 5-GACCTTGTCTGGAAAGATCC-3
(sense, 25 to 5; 30 pmol) and 5-CAGGCTGATCACCAC-
CATCA-3 (antisense, 844–860; 30 pmol) (34, 35). After PCR,
the amplified cDNA products (319 bp) were separated on 1.5%
agarose gel and stained with ethidium bromide. -Actin was
amplified, as a loading control.
Microarray analysis in BLM cells
BLMmelanoma cells were seeded (5 105 cells/10-cm tissue
culture dishes); after 48h, cellswere treatedwithGnRH-A (106
M) for 24 h, and total RNA was prepared as described above.
After quality control using a bioanalyzer (Agilent 2100), RNAs
were labeled according to the Affymetrix protocol using One
Cycle Labeling kit (Affymetrix, Santa Clara, CA). Fifteen mi-
crograms of resulting cRNAs were hybridized onto whole-ge-
nome microarray U133 Plus 2.0. After hybridization on Af-
fymetrix HG-U133 Plus 2.0 chips, gene expression values were
estimated for each probe set using packages in the Bioconductor
suite (36). Genes were normalized and analyzed with both the ro-
bustmultichipanalysis (RMA)methodwithin theaffypackage (37,
38) and corrected for GC content with the GCRMApackage (39).
Thedifferences in logexpression levels forbothRMAandGCRMA
normalized data were evaluated by the two-tailed t test as imple-
mented in the limma package (40). GeneswithP values0.05 and
theabsolute expression fold changegreater than2 (logdifferenceof
1)were considered as significantly differentially expressed between
treated and untreated cells. A gene list was generated by taking the
overlap of significantly differentially expressed genes generated by
limma from both the RMA andGCRMAnormalization methods.
TheprobesusedtoanalyzeVEGFexpressionwereselectedtodetect
all VEGFA isoforms.
Real-time PCR analysis for VEGF expression in
BLM cells
To confirm the effects of GnRH-A on VEGF expression in
BLMcells, real-time PCRanalysis was performed initially on the
same RNA samples submitted to microarray analysis and then
on new experimental setups. In these subsequent experiments,
BLM melanoma cells were seeded (5  105 cells/10-cm tissue
culture dishes) in 10% FBS-supplemented medium. After 48 h,
cells were treated with GnRH-A (106 M) for different time in-
tervals (6, 12, 24, and 36 h). At the end of the treatment, RNA
was extracted and reverse transcribed using the High Capacity
cDNAArchive kit (Applied Biosystems). The resulting cDNAs
were amplified by real-time PCR using TaqMan polymerase
and primers Hs 00903129m1 (Applied Biosystems). The
primers were designed by the manufacturer using Primer Ex-
pression version 1 (Applied Biosystems) based on the sequence
of the human VEGFA from the GenBank database (accession
no. NM_003376-4). The probes were selected to detect all
VEGFA isoforms. The 18S ribosome RNA was used as a nor-
malizing unit for each reaction, using a set of primers pur-
chased as a kit (TaqMan Ribosomal RNA Control Reagents
kit; Applied Biosystems).
Real-timePCRanalysiswas performedby theRealTimePCR
Service, Cogentech (Fondazione Italiana per la Ricerca sul Can-
cro, Institute of Molecular Oncology Foundation, European In-
stitute of Oncology Campus, Milan, Italy).
RT-PCR analysis of VEGF165 and VEGF121 isoform
expression in BLM cells
Experiments were performed to verify whether the different
VEGF isoforms (VEGF121, VEGF145, VEGF165, and VEGF189),
derived from alternative splicing of the same pre-mRNA might
be expressed inBLMmelanomacells.RNA(1g) extracted from
BLM cells was reverse transcribed, as described above. cDNA
amplification was then performed in the presence of a set of
primers (sense, 5-TCGGGCCTCCGAAACCATGA-3; anti-
sense, 5-CCTGGTGAGAGATCTGGTTC-3) recognizing all
the VEGF isoforms (41).
Experimentswere thenperformed to verifywhetherGnRH-A
might affect the expression of the VEGF isoforms. Specifically,
we focused our attention on VEGF165, the key protein in angio-
genesis induction, andVEGF121, themost abundantly expressed
isoform in BLM cells, according to our results. To this purpose,
BLM melanoma cells were seeded (7  105 cell/10-cm tissue
culture dishes) in 10% FBS-supplemented medium. After 48 h,
cells were treated with GnRH-A (106 M) for different time in-
tervals (6, 12, 24, and 36 h). At the end of the treatment, RNA
was extracted and reverse transcribed. Preliminary experiments
were performed to choose the most appropriate PCR conditions
(temperatures and number of cycles) (data not shown). For
VEGF165 cDNA amplification, 2 g RNA was reverse tran-
scribed, and PCR conditions were as follows: 25-s denaturation
at 95 C, 25-s primer annealing at 58 C, and 25-s primer ex-
tension at 72 C, for 27 cycles, using the common sense VEGF
primer (5-CCCTGATGAGATCGAGTACATCTT-3) and the
VEGF165-specific antisense primer (5-GCCTCGGCTTGTCA-
CATTTT-3) (41). For VEGF121 cDNA amplification, 1 g
RNAwas reversed transcribed, and PCR conditions were as fol-
lows: 25-s denaturation at 95 C, 25-s primer annealing at 58 C,
and 25-s primer extension at 72 C, for 30 cycles, using the com-
mon sense VEGF primer (5-CCCTGATGAGATCGAGTA-
CATCTT-3) and the VEGF121-specific antisense primer (5-
AGCAAGGCCCACAGGGATTT-3) (41). -Actin expression
was amplified, as a control. After PCR, the amplified cDNA
products were separated on 1.5% agarose gel and stained with
ethidium bromide. The experiments were repeated three times.
The bands were quantified by densitometry, and the ratios be-
tween either VEGF165 or VEGF121 and -actin levels were taken
into account for statistical analysis.
ELISA assay for VEGF165 secretion from BLM cells
BLM cells were seeded (2  104 cells per well) in 24-well
plates and cultured in 10%FBS-supplementedmedium for 48 h.
The medium was then changed to 1% FBS-supplemented me-
dium, and cellswere treatedwithGnRH-A (106M) for different
time intervals (6, 24, 48, and 72 h). At the end of each incubation
period, themediumwas collectedandcentrifugedat1000g for
10 min. VEGF protein levels were then evaluated, in collected
supernatants, using an ELISA (Quantikine Human VEGF Im-
munoassay; R & D Systems), specifically recognizing the
VEGF165 isoform, according to the instructions of the manufac-
turer. An enzyme immunoassay multi-well reader set to read at
an emission of 450 nm was used to quantify the results. The
sensitivity of the assay was 5 pg/ml. Three separate experiments
were performed.
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HUVEC chemotactic assay
To evaluate the motility of HUVECs toward different che-
moattractants, chemotactic assays were conducted using the 48-
well Boyden’s chamber (Neuroprobe, Cabin John, MD), in
which each pair of wells were separated by polyvinylpyrroli-
done-free polycarbonate porous membrane (8 m pore size)
(29). HUVECs were seeded (2.5  104 cells/50 l) in the open-
bottom wells of the chemotaxis chambers. The lower compart-
ments of the chamber were filled with the following chemoat-
tractants: 1% FBS medium, GnRH-A (106 M) in 1% FBS
medium;VEGF165 (10ng/ml) in 1%FBSmedium.The chambers
were then incubated for 4 h at 37 C in the cell culture incubator.
Cells that hadmigrated through the pores and found adherent to
the underside of the membrane were fixed and stained (Diff-
Quick kit; Dade, Dudingen, Switzerland). Six random objective
fields of stained cells were counted for each well. The ability of
HUVECs to migrate toward the culture medium of BLM cells,
treated or not with GnRH-A, was investigated. To this purpose,
BLM cells (5  105 cells per dish) were seeded in 6-cm tissue
culture dishes, in 10% FBS-supplemented medium. After 48 h,
the medium was changed to 1% FBS-supplemented medium, in
either the absence or presence of GnRH-A (106 M) for 24, 48,
or 72 h. At the end of the treatment, the media (conditioned
medium) were collected and centrifuged at 1000 g for 10 min
and assayed as chemoattractant. A chemomigration assay of
HUVECs was then performed, as described above, by filling the
lower compartment of the Boyden’s chamber with conditioned
media fromBLMcells, eitheruntreatedor treatedwithGnRH-A.
Each experiment was performed three times.
HUVEC proliferation studies
HUVECswere plated (2.5 104 cells per dish) in 6-cmdishes
in culture medium. Cells were allowed to attach and start grow-
ing for 24 h; the seeding media were then changed to serum-
starvedmedia and treatedwithVEGF165 (10ng/ml, dose selected
on the basis of preliminary experiments), in either the absence or
presence of GnRH-A (106 M), for 4 d. The specificity of the
activity ofGnRH-Awas assessed by treatingHUVECswith both
VEGF and GnRH-A, in the presence of the GnRH-A antagonist
GnRH-Ant (106 M). At the end of the treatment, cells were
collected and counted by hemocytometer.
Tube formation assay
The ability of HUVECs to form capillary-like structures was
measured on a layer of reconstituted basement membrane ma-
trix (Matrigel; BD Biosciences) added to the 96-well tissue
culture plate (13.47mg/ml, 100l/well) at 4 C.HUVECswere
trypsinized, counted, resuspended in culture medium, and
seeded on the top of the reconstituted basement membrane (1
104 cells per well). After 30 min at 37 C, the medium was
changed, and cells were treated with VEGF (10 ng/ml), either
alone or in the presence of GnRH-A (106 M). The specificity of
the activity of GnRH-A was assessed by treating HUVECs with
both VEGF andGnRH-A, in the presence of GnRH-Ant (106 M).
After 18 h, capillary tube formation was assessed, as described
previously (42), under an inverted microscope at 40 magnifi-
cation. Quantification of tube formation was performed by
counting nine randommicroscopic fields (40) per sample,with
each condition being assessed in triplicate.
Statistical analysis
When appropriate, data were analyzed by Bonferroni’s test
after one-way ANOVA.
Results
Expression of GnRH-R in melanoma cell lines from
tumors at different stages of progression
We showed previously that GnRH-R are expressed, at
both mRNA and protein level, in BLM melanoma cells
(29). Here, we investigated the expression of the receptor
in a panel of cell lines derived from human melanomas at
different stages of the disease. ByRT-PCR,we could show
that the mRNA coding for the GnRH-R is expressed in
cells derived from nonmetastatic tumors (Fig. 1A, lanes
1–5) and in cells derived frommalignant melanomas (Fig.
1B, lanes 1–8). Figure 1B also shows that the level of ex-
pression of the receptor seems to be similar in cells from
primary lesions and from metastases, indicating that no
loss ofGnRH-R takes place during themetastatic process,
confirming previous observations (43).
FIG. 1. Expression of GnRH-R in a panel of melanoma cell lines derived
from tumors at different stages of progression. A, Expression of GnRH-R
in melanoma cells derived from nonmetastatic tumors. Lanes 1–5,
BLM, WM793, WM902, WM1341, WM1552; lane 6, pAW109,
internal standard; M, molecular weight marker (1000–100 bp).
B, Expression of GnRH-R in melanoma cells derived from primary
metastatic melanomas or metastasis. Lanes 1, 2, WM115 and
WM239A (primary and metachronous metastasis); lane 3, WM373
(metastasis); lanes 4, 5, WM278A and WM1617 (primary and
metachronous metastasis); lanes 6, 7, WM983A and WM983B
(primary and synchronous metastasis); lane 8, WM9 (metastasis); lane
9, pAW109, internal standard; M, molecular weight marker (1000–
100 bp).
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GnRH agonists decrease VEGF
expression in melanoma cells
We reported previously that GnRH
agonists significantly reduce the growth
and the motility of BLM cells (29, 31).
Experiments were performed to inves-
tigate whether GnRH agonists might
affect the expression of genes involved
in the malignant progression of mela-
noma. BLM cells were treated with
GnRH-A (106 M) for 24 h, and changes
in gene expression profile were evalu-
ated by genome-wide transcriptomic
analysis (Affymetrix Human Genome
U133 Plus 2.0 Array).
A representative heat map showing
changes in gene expression is reported
in Fig. 2A.Datawere compiled for gene
expressionof two separate controls and
two treated samples. Genes with P val-
ues 0.05 and the absolute expression
fold change greater then 2 (log differ-
ence of 1) are considered as signifi-
cantly differentially expressed between
treated and untreated cells (Fig. 2B).
The arrow points to VEGF as a down-
regulated gene after the treatment (Fig.
2A). For a color version of these data,
see Supplemental Fig. 1 (published on
The Endocrine Society’s Journals On-
line web site at http://endo.endojour-
nals.org). To confirm this observation,
real-time PCR analysis was first per-
formed on the same RNA samples an-
alyzed previously by microarray. Fig-
ure 2C confirms that, in BLM cells, the
expression of VEGF mRNA is signifi-
cantly reduced 24 h after GnRH-A
treatment. In subsequent experiments,
the expression of VEGF at different
time intervals after the treatment with
GnRH-A (6–36 h) was analyzed. Fig-
ure 2D shows that the expression of
VEGF is substantially decreased at all
the time intervals considered (lanes 2–5
vs. lane 1).
GnRH agonists decrease VEGF165,
but not VEGF121, isoform
expression in melanoma cells
It is known that different VEGF iso-
forms are generated by alternative
splicing of the same primary transcript
FIG. 2. GnRH agonists decrease VEGF expression in BLM cells. A, B, BLM cells were treated
with GnRH-A (106 M) for 24 h. RNA was extracted and changes in gene expression profile
were evaluated by genome-wide transcriptomic analysis (Affymetrix Human Genome U133
Plus 2.0 Array), as described in Materials and Methods. A, Representative heat map showing
changes in gene expression. Data were compiled for gene expression of two separate controls
and two separate treated samples. The arrow points to VEGF as a downregulated gene after
treatment. B, Analysis with Bioconductor shows gene expression values estimated for each
probe set using the RMA and corrected for GC content with the GCRMA method applied to
all samples simultaneously. Absolute fold change greater then 2 is expressed as log difference
of 1 above background control. Genes with P values  0.05 and the absolute expression fold
change greater than 2 (log difference of 1) were considered as significantly differentially
expressed between treated and untreated cells. C, Real-time PCR analysis of VEGF expression
in BLM cells was performed on the same RNA samples submitted to microarray analysis. C,
Untreated controls; GnRH-A, BLM cells treated with GnRH-A for 24 h. D, Real-time analysis of
VEGF expression in BLM cells treated with GnRH-A (106 M) for different time intervals. Lane
1, Untreated controls; lane 2, 6 h; lane 3, 12 h; lane 4, 24 h; lane 5, 36 h. The 18S ribosome
RNA was used as a normalizing unit for each reaction. RQ, Relative level of gene expression;
RQ min/RQ max, error bars based on the confidence interval (95%). Results of one from three
experiments performed are reported.
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(44). ByRT-PCR,we first demonstrated that the fourVEGF
isoforms,VEGF121,VEGF145,VEGF165, andVEGF189 (cor-
responding to 530, 590, 680, and 700 bp) are expressed in
BLMcells (Fig. 3). Then, by using specific primers (41),we
investigated the effects of GnRH-A specifically on the ex-
pression of the VEGF165 isoform, the key protein in an-
giogenesis induction, and of the VEGF121, the most abun-
dantly expressed isoform in BLM cells (Fig. 3). Cells were
treatedwithGnRH-A (106 M) for different time intervals
(6, 12, 24, and 36 h). Figure 4, A and B, shows that
GnRH-A significantly decreases VEGF165 expression at
12 and 24 h of treatment. On the contrary, GnRH-A does
not significantly affect the expression of VEGF121, at any
time intervals considered (Fig. 5, A and B). Interestingly,
the levels of VEGF165 (and also those of VEGF121) expres-
sion decrease over time in control cells (Figs. 4, A and B,
and 5, A and B). The reason for this decrease is unclear;
however, we might speculate that changing the culture
media, at the beginning of the treatment, with freshmedia
might stimulate the growth factor expression. This stim-
ulation then decreases over time.
GnRH agonists decrease VEGF165 secretion from
melanoma cells
To confirm the impact of the changes in VEGF mRNA
levels on its translation and release, we analyzed VEGF165
levels in the conditioned media of BLM cells treated with
GnRH-A (106 M) for different time intervals (6, 24, 48,
and 72 h). Figure 6A shows that the secretion of the
VEGF165 isoform from BLM cells is significantly reduced
after 24, 48, and 72 h of treatment. Thus, GnRH agonists
exert an inhibitory effect on VEGF synthesis and on its
subsequent secretion from melanoma cells.
Given the decreased secretion of VEGF from GnRH-
A-treated BLM cells, we next investigated the chemoat-
tractant effects of the conditioned media of GnRH-A-
treated cells on the migratory behavior of HUVECs, a
biological function mediated by VEGF (45). We first con-
FIG. 3. RT-PCR analysis showing the expression of the different VEGF
isoforms in BLM cells (lane 1). M, Molecular weight marker (1000–100 bp).
FIG. 5. GnRH agonists do not affect VEGF121 isoform expression in
BLM cells. A, RT-PCR analysis of the expression of the VEGF121 isoform
in BLM cells treated with GnRH-A (106 M). -Actin was amplified as a
control. One representative of three different experiments is shown
here. B, Densitometric analysis of the data reported in A. The bands
were quantified by densitometry, and the ratios between VEGF121 and
-actin levels were taken into account for statistical analysis. The
results are expressed as a percentage of the relative VEGF121/-actin
ratios in untreated controls (C) at 6 h.
FIG. 4. GnRH agonists decrease VEGF165 isoform expression in BLM
cells. A, RT-PCR analysis of the expression of the VEGF165 isoform in
BLM cells treated with GnRH-A (106 M). -Actin was amplified as a
control. One representative of three different experiments is shown
here. B, Densitometric analysis of the data reported in A. The bands
were quantified by densitometry, and the ratios between VEGF165 and
-actin levels were taken into account for statistical analysis. The
results are expressed as a percentage of the relative VEGF165/-actin
ratios in untreated controls (C) at 6 h. *, P  0.05 vs. controls (C).
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firmed that VEGF165 represents a chemotactic stimulus
for HUVECs, whereas in the same assay, GnRH-A was
devoid of any effect (Fig. 6B). Then, BLM cells were
treated with GnRH-A (106 M) for 24, 48, or 72 h; the
conditioned media were placed in the lower well of the
Boyden’s chamber, as the chemoattractant. Figure6Cshows
that the number of HUVECsmigrating toward the medium
of BLMcells pretreated (72 h) withGnRH-A is significantly
lower than the number of cells migrating toward the condi-
tioned medium of untreated cells. At shorter treatments (24
and 48 h), the conditioned medium of BLM cells does not
affect the migration of HUVECs (data not shown). To ex-
plain this observation, we hypothesize that other factors in-
terferingwith the activity of secretedVEGFmight be present
in the conditioned medium of BLM cells.
GnRH agonists counteract VEGF-stimulated HUVEC
proliferation
To study whether GnRH agonists could directly affect
the angiogenic properties of endothelial cells, the expres-
sion of theGnRH-Rwas investigated inHUVECs. ByRT-
PCR, we found that the mRNA coding for this receptor is
expressed in HUVECs (Fig. 7A, lane 2), as well as in BLM
cells (Fig. 7A, lane 1), used as a control. This suggests that
GnRH agonists might exert an additional, direct effect on
tumor angiogenesis.
To investigatewhetherGnRHagonistsmight affect en-
dothelial cell proliferation,HUVECswere treated, for 4 d,
with VEGF165 (10 ng/ml), either alone or in the presence
of GnRH-A (106 M). As expected, VEGF165 significantly
stimulated HUVEC proliferation, whereas GnRH-A, given
alone, did not affect endothelial cell growth. In contrast, the
GnRH agonist significantly counteracted the proliferative
activity of VEGF165 (Fig. 7B). The activity of GnRH-A is
specific because it is completely counteracted by the
cotreatment of the cells with the GnRH antagonist
GnRH-Ant (Fig. 7B).
FIG. 7. GnRH agonists counteract the proliferative activity of VEGF165
on HUVECs. A, RT-PCR analysis showing the expression of GnRH
receptors in HUVECs. Lane 1, BLM cells used as a control; lane 2,
HUVECs. B, HUVECs were treated daily, for 4 d, with VEGF165 (10 ng/
ml) and GnRH-A (106 M), either alone or in combination. The
specificity of GnRH-A activity was assessed by cotreating the cells with
a GnRH antagonist (GnRH-Ant). Results are expressed as the number
of cells per well and represent the results from three separate
experiments. Values are represented as the mean  SE. *, P  0.05 vs.
untreated controls (C). **, P  0.05 vs. VEGF165-treated cells.
FIG. 6. GnRH agonists decrease VEGF165 secretion from BLM cells.
A, BLM cells were treated with GnRH-A (106 M) for 6, 24, 48, or
72 h. VEGF levels were analyzed, in collected supernatants, using
an ELISA, specifically recognizing the VEGF165 isoform. Data are
expressed as picograms per milliliter of VEGF165 in the culture
medium and represent the results from three separate experiments.
*, P  0.05 vs. untreated controls (C). B, Chemotactic assay performed
to evaluate the ability of HUVECs to move toward VEGF165. HUVECs
were seeded in the open-bottom well of a chemotaxis chamber. The
lower compartments were filled with the following: 1% FBS-RPMI
medium (C), GnRH-A (106 M) in 1% FBS-RPMI medium; VEGF165 (10
ng/ml) in 1% FBS-RPMI medium. After 4 h at 37 C, the cells that had
migrated through the pores and found adherent to the underside of
the membrane were fixed and stained. Six random objective fields of
stained cells were counted for each well. Data are expressed as
number of migrated cells per square centimeters and represent the
results from three separate experiments. *, P  0.05 vs. untreated
controls (C). C, Chemotactic assay performed to evaluate the ability of
HUVECs to move toward medium conditioned by BML cells. Cells were
treated for 72 h with GnRH-A (106 M). The conditioned media from
both untreated (controls, CMC) and treated (CMGnRH-A) cells were
collected and used as the chemoattractant in the lower compartments
of the chemotaxis chamber. Chemotactic assay was performed as
described in B. Data are expressed as number of migrated cells per
square centimeters and represent the results from three separate
experiments. Values are represented as the mean  SE. *, P  0.05 vs.
untreated controls (C).
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GnRH agonists counteract VEGF-stimulated
endothelial cells in vitro tube formation
Having established that GnRH-A counteracts VEGF-
induced HUVEC proliferation, we then examined its im-
plication in the angiogenic process in vitro. For these stud-
ies, we used a conventional angiogenesis test, based on the
ability of endothelial cells to spontaneously form capil-
lary-like structures, when incubated on an extracellular
basement membrane matrix preparation (Matrigel). Fig-
ure 8A shows that, in the absence of serum,HUVECs lack
the ability to undergo alignment into capillary-like struc-
tures. VEGF strongly induces the process of tube forma-
tion (Fig. 8C), whereas GnRH-A, given alone, is not able
to affect the formation of capillaries (Fig. 8B). GnRH-A
substantially counteracts the effects of VEGF (Fig. 8D);
the activity of GnRH-A is specific be-
cause it is completely counteracted by
the cotreatment of the cells with the
GnRH antagonist GnRH-Ant (Fig.
8E). Tube formation was quantified by
counting the number of endothelial cell
structures, as summarized in Fig. 8F.
These results demonstrate that the ac-
tivation of locally expressed GnRH-R
interferes with the VEGF-induced ca-
pability of endothelial cells to formcap-
illary-like structures.
Discussion
We showed previously that high-affin-
ity GnRH-R are expressed in two hu-
man melanoma cell lines, BLM and
Me15392. To confirm this observa-
tion, and before further unraveling the
role played by these receptors in mela-
noma progression, we analyzed the ex-
pression of GnRH-R in a panel of hu-
man melanoma cell lines derived from
either nonmetastatic or intermediate/
highly metastatic primary tumors and
from metastasis. We observed that the
receptors are expressed in all the tumor
samples tested, independent of their
malignant behavior, in agreement with
previously published data (43).
We then sought to identify genes
whose expression might be specifically
regulated by GnRH-R activation. To
this purpose, by using the Affymetrix
Human Genome U133 Plus 2.0 Array,
we investigated the gene expression
profile in melanoma cells treated with a GnRH agonist
(GnRH-A). Among the other genes whose expression was
increased included the following: HSPA1B, which has
been shown to activate T cells recognizing melanoma dif-
ferentiation antigens (46); and DHK1, the antagonist of
the canonical Wnt signaling pathway, endowed with tu-
mor suppressor activity (47). Among the genes whose ex-
pression was reduced was CSPG2 (chondroitin sulfate
proteoglycan2, versican), a proteoglycan of the extracel-
lular matrix that is overexpressed in melanoma and con-
tributes to melanoma progression, favoring the detach-
ment of the cells and the metastatic dissemination (48).
These data look particularly intriguing and certainly de-
serve additional investigation.
FIG. 8. GnRH agonists counteract the ability of VEGF165 to induce HUVECs tube formation.
A, HUVECs were seeded on the top of a reconstituted basement membrane and treated with
VEGF165 (10 ng/ml) and GnRH-A (10
6 M), either alone or in combination, for 18 h (A–D). The
specificity of GnRH-A activity was assessed by cotreating the cells with a GnRH antagonist
(GnRH-Ant) (E). F, Number of tubes was measured, and data represent the results from three
separate experiments. Data were analyzed by ANOVA followed by Bonferroni’s test. Values
are represented as the mean  SE. *, P  0.05 vs. untreated controls (C). **, P  0.05 vs.
VEGF165-treated cells.
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In our genome-wide transcriptomic analysis, we found
that GnRH-A significantly reduced the expression of
VEGF, and, given the pivotal role of this growth factor in
the process of angiogenesis, we focused our attention on
this gene. By real-time PCR and comparative PCR, we
confirmed that GnRH-A significantly reduces the expres-
sion of VEGF, and specifically the VEGF165 isoform, in
BLM cells. Consistently, the amount of VEGF165 secreted
from melanoma cells was also found to be significantly
reduced. Thus, we hypothesized that treatment of mela-
noma cells withGnRHagonists might reduce the capacity
of these cells to attract endothelial cells, thus interfering
with the process of neo-angiogenesis. Indeed, we found
that the ability of HUVECs to move toward the condi-
tionedmedia of BLMcells was significantly reducedwhen
the cells were pretreated with a GnRH agonist. Together,
these observations strongly indicate that GnRH agonists
might decrease the pro-angiogenic activity of melanoma
cells by reducing the expression/secretion/activity of
VEGF. Accordingly, the expression of VEGF has been
shown to be significantly reduced in human endometrial
cell cultures (49), aswell as in humanuterinemyomas (50)
after treatment with GnRH agonists, although in these
studies the effect on the pro-angiogenic activity was not
reported. Interestingly, VEGF immunostaining has been
found to be decreased in prostate cancer tissues of pa-
tients undergoing complete androgen blockade therapy
(bicalutamide  goserelin acetate); however, a specific
direct effect of the GnRH agonist has not been ad-
dressed in this clinical study (51). In female rats, GnRH
analogs have been reported to regulate follicular devel-
opment through a down-regulation of VEGF expression
in ovarian follicles (52).
In previous papers, we have demonstrated that GnRH
analogs significantly inhibit the proliferation aswell as the
migratory/invasive behavior of BLM melanoma cells (by
reducing the expression/activity of 3 integrin and
MMP-2) (29, 31). The data here reported further confirm
a direct antitumor activity of GnRH agonists on mela-
noma cells, while indicating a novel (i.e. anti-angiogenic)
mechanismof action, throughVEGF. In partial agreement
with our observations, Keller et al. (43) reported the pres-
ence of GnRH-R in melanoma cells; treatment of nude
mice bearing human melanoma xenografts with a cyto-
toxic analog of GnRH (GnRH agonist chemotherapeu-
tic agent) results in a significant decrease of tumor volume.
However, it must be underlined that these authors did not
directly address the antitumor activity of GnRH agonists
onmelanoma growth. In their study, they used the GnRH
agonist as the carrier molecule that, by binding to
GnRH-R on melanoma cells, can specifically target a cy-
totoxic compound at the level of tumor cells.
As mentioned, we showed previously that GnRH ago-
nists significantly reducemelanomacell proliferation (29).
Moreover, it is known that tumor cellsmay express VEGF
receptors and that VEGF, through these receptors, may
stimulate tumor cell proliferation. Thus, it is possible to
speculate that the antiproliferative effect of GnRH ago-
nists might not be direct but mediated by a reduced VEGF
secretion. We ruled out this possibility by demonstrating
that BLM cells do not express the VEGF receptor and,
accordingly, VEGF does not modify BLM cell prolifera-
tion (data not shown).
In the past, the direct antitumor activity of GnRH ago-
nists has been extensively demonstrated in endocrine-re-
lated tumorsbyus (23–25) aswell asbyother investigators
(20–22). These observations have later been supported by
clinical data, indicating that expression of GnRH-R is a
favorableprognostic factor inbothprostate (53) andovar-
ian cancers (54).
Surprisingly, in this paper, we found that GnRH-R are
expressed also in HUVECs. These receptors are func-
tional, because their activation reducesVEGF-inducedcell
proliferation and ability to form capillary-like structures.
To our knowledge, this is the first report of a direct effect
of GnRH agonists on the angiogenic process. This obser-
vation is particularly relevant because it indicates that
GnRH agonists might exert an antitumor effect on mela-
nomas (and, in general, on tumors expressing GnRH-R)
not only by reducing tumor cell proliferation and meta-
static behavior but also by counteracting the process of
angiogenesis, both indirectly by reducing VEGF secretion
from tumor cells and directly by interfering with the
VEGF-induced process of angiogenesis.
In previous papers, we demonstrated that, in prostate
cancer cells, GnRH agonists reduce the proliferation and
the migratory/invasive behavior of the cells by counter-
acting the activity of epidermal growth factor (55) and
IGF-I (56, 57). Here, we show that these compounds re-
duce VEGF secretion/activity from tumor cells and inter-
fere with the pro-angiogenic activity of the growth factor
on endothelial cells. Thus, GnRH agonists exert a signif-
icant inhibitory effect on tumor progression and neoan-
giogenesis, by interfering with the activity of the growth
factors that specifically favor these processes.
In conclusion, in the present paper,we demonstrated that
GnRHagonists reduceVEGFsecretion frommelanomacells
(less growth factor is made available in the tumor microen-
vironment to stimulate angiogenesis) and in addition coun-
teract the pro-angiogenic effects exerted by VEGF on endo-
thelial cells (proliferation and cord formation). GnRH-R
might represent a molecular target for the development of
novel therapeutic interventions in melanoma.
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